Skip to main content
    D

    DexCom Inc (DXCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $81.61
    -1.72 (-2.06%)

    Market Cap: $31.08B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    DexCom Inc (DXCM) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    DexCom reported revenue of $4.66B for the fiscal year ended Dec 31, 2025, up 15.6% from the year before. That year, net income was $836.30M with a net margin of 17.9%, operating cash flow was $1.44B and free cash flow was $1.08B. The quarter ended Sep 30, 2026 had revenue of $1.34B and net income of $275.10M.

    Revenue and Margins

    The operating margin was 19.6% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $573.30M, a compound annual rate of 26.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.66B+15.6%60.1%19.6%17.9%
    Dec 2024$4.03B+11.3%60.5%14.9%14.3%
    Dec 2023$3.62B+24.5%63.2%16.5%14.9%
    Dec 2022$2.91B+18.8%64.7%13.4%11.7%
    Dec 2021$2.45B+27.1%68.6%10.9%8.9%
    Dec 2020$1.93B+30.5%66.4%15.5%28.5%
    Dec 2019$1.48B+43.1%63.1%9.6%6.8%
    Dec 2018$1.03B+43.6%64.4%-18.1%-12.3%
    Dec 2017$718.50M+25.3%68.5%-5.9%-7.0%
    Dec 2016$573.30MN/A66.0%-11.1%-11.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 45.1% from the year before. In the quarter ended Sep 2026, net income fell 3.1% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.66B$4.03B$3.62B$2.91B$2.45B$1.93B$1.48B$1.03B$718.50M$573.30M
    Cost of revenue$1.86B$1.59B$1.33B$1.03B$768.00M$646.60M$544.50M$367.70M$226.40M$194.90M
    Gross profit$2.80B$2.44B$2.29B$1.88B$1.68B$1.28B$931.50M$663.90M$492.10M$378.40M
    Research and development$599.10M$552.40M$505.80M$484.20M$604.20M$359.90M$273.50M$417.40M$185.40M$156.10M
    Operating income$911.80M$600.00M$597.70M$391.20M$265.80M$299.50M$142.30M-$186.30M-$42.50M-$63.90M
    Net income$836.30M$576.20M$541.50M$341.20M$216.90M$549.70M$101.10M-$127.10M-$50.20M-$65.60M
    EBITDA$1.34B$926.70M$896.40M$546.70M$358.80M$382.70M$217.40M-$154.80M-$10.30M-$48.80M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.34B$1.31B$1.19B$1.26B$1.21B$1.16B$1.04B$1.11B$994.20M$1.00B$921.00M$1.03B
    Gross profit$864.40M$830.00M$750.30M$792.70M$731.40M$688.80M$589.00M$655.80M$593.80M$626.70M$561.90M$656.60M
    Operating income$327.20M$318.30M$255.30M$323.00M$242.50M$212.60M$133.70M$188.90M$152.00M$158.00M$101.10M$216.90M
    Net income$275.10M$249.10M$199.50M$267.30M$283.80M$179.80M$105.40M$151.70M$134.60M$143.50M$146.40M$256.30M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $1.26B exceeded cash and equivalents by $344.80M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$6.34B$6.48B$6.26B$5.39B$4.93B$4.29B$2.40B$1.92B$904.10M$402.80M
    Current assets$4.03B$4.30B$4.43B$3.67B$3.68B$3.42B$1.97B$1.70B$744.70M$280.00M
    Cash and equivalents$917.70M$606.10M$566.30M$642.30M$1.05B$817.60M$446.20M$1.14B$441.50M$94.50M
    Total liabilities$3.59B$4.38B$4.20B$3.26B$2.89B$2.46B$1.51B$1.25B$484.70M$119.00M
    Short-term debt$21.60M$1.20B$0$772.60M$0$16.50M$13.60M$11.70M$33.40M$39.10M
    Long-term debt$1.24B$1.24B$2.43B$1.20B$1.98B$1.67B$1.06B$1.01B$327.60M$0
    Shareholder equity$2.75B$2.10B$2.07B$2.13B$2.04B$1.83B$882.60M$663.30M$419.40M$283.80M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$6.24B$6.46B$6.63B$6.34B$7.50B$7.33B$6.75B$6.48B$6.35B$6.80B$6.48B$6.26B
    Total liabilities$3.70B$3.83B$3.68B$3.59B$4.77B$4.75B$4.49B$4.38B$4.37B$4.36B$4.24B$4.20B
    Cash and equivalents$961.40M$1.10B$1.12B$917.70M$1.84B$1.16B$904.90M$606.10M$621.20M$939.20M$851.20M$566.30M
    Shareholder equity$2.54B$2.62B$2.96B$2.75B$2.73B$2.57B$2.27B$2.10B$1.98B$2.43B$2.25B$2.07B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 75.0% of operating cash flow. Share repurchases came to 46.3% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.44B$989.50M$748.50M$669.50M$442.50M$475.60M$314.50M$123.20M$92.00M$56.20M
    Capital expenditures$363.50M$358.80M$236.60M$364.80M$389.20M$199.00M$180.00M$67.10M$66.00M$55.70M
    Free cash flow$1.08B$630.70M$511.90M$304.70M$53.30M$276.60M$134.50M$56.10M$26.00M$500.00K
    Dividends paidN/AN/A$1.23BN/AN/AN/AN/AN/A$0$0
    Share repurchases$500.00M$750.00M$688.70M$557.70M$0$0N/A$100.00M$0$0
    Investing cash flow$536.00M-$207.50M-$507.20M-$521.50M-$216.10M-$1.02B-$1.02B-$139.80M-$144.40M-$55.90M
    Financing cash flow-$1.69B-$734.80M-$318.60M-$552.50M$10.40M$912.10M$10.70M$710.40M$399.10M$8.10M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$325.60M$269.20M$525.60M$294.00M$659.90M$303.00M$183.80M$301.40M$199.50M$279.40M$209.20M$133.60M
    Capital expenditures$52.90M$84.70M$76.60M$101.90M$80.50M$94.10M$87.00M$124.60M$111.20M$66.10M$56.90M$52.50M
    Free cash flow$272.70M$184.50M$449.00M$192.10M$579.40M$208.90M$96.80M$176.80M$88.30M$213.30M$152.30M$81.10M
    Last 12 quarters

    Frequently Asked Questions About DXCM

    What is DexCom's annual revenue?

    DexCom reported revenue of $4.66B for the fiscal year ended Dec 31, 2025.

    How fast is DexCom's revenue growing?

    Revenue was up 15.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 17.0%.

    Is DexCom profitable?

    Yes. DexCom reported net income of $836.30M for the fiscal year ended Dec 31, 2025, with a net margin of 17.9%.

    How much free cash flow does DXCM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.44B minus capital expenditures of $363.50M produced free cash flow of $1.08B.

    How much debt does DexCom have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.24B, short-term debt of $21.60M and cash and equivalents of $917.70M.